You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Celldex

Showing 1 - 25 of 59
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Melanoma, Metastatic Melanoma Trial in Boston (CDX-301, NEOVAX, Nivolumab)

Recruiting
  • Melanoma
  • Metastatic Melanoma
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Jan 12, 2023

Pancreatic Cancer, Cancer of the Pancreas, Pancreas Cancer Trial in Saint Louis (CDX-301, CDX-1140, Research blood draw)

Recruiting
  • Pancreatic Cancer
  • +2 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 17, 2023

Metastatic Pancreatic Adenocarcinoma Trial (odetiglucan, CDX-1140)

Not yet recruiting
  • Metastatic Pancreatic Adenocarcinoma
  • odetiglucan
  • CDX-1140
  • (no location specified)
Jul 29, 2022

B Cell Lymphoma Trial in United Kingdom (Varlilumab)

Active, not recruiting
  • B Cell Lymphoma
  • Manchester, United Kingdom
  • +3 more
Oct 26, 2022

Non Small Cell Lung Cancer, Lung Cancer Trial in Bronx (drug, biological, radiation)

Recruiting
  • Non Small Cell Lung Cancer
  • Lung Cancer
  • FLT3 Ligand (CDX-301)
  • +2 more
  • Bronx, New York
    Albert Einstein College of Medicine
Jul 18, 2022

Metastatic Triple Negative Breast Cancer Trial in Dallas (PLD Chemotherapy, CDX-1140, CDX-301)

Recruiting
  • Metastatic Triple Negative Breast Cancer
  • PLD Chemotherapy
  • +2 more
  • Dallas, Texas
    UT Southwestern Medical Center
Jun 23, 2022

Malignant Epithelial Tumors Trial in Portland (TCR-transduced T cells, CDX-1140, Pembrolizumab)

Not yet recruiting
  • Malignant Epithelial Neoplasms
  • TCR-transduced T cells
  • +2 more
  • Portland, Oregon
    Providence Portland Medical Center
Apr 22, 2022

NSCLC (NSCLC) Trial in Bronx (FLT3 Ligand Therapy (CDX-301), Stereotactic Body Radiotherapy (SBRT))

Active, not recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • FLT3 Ligand Therapy (CDX-301)
  • Stereotactic Body Radiotherapy (SBRT)
  • Bronx, New York
    Montefiore Medical Center
Nov 5, 2021

Breast Cancer Trial in United States (radiation, drug, biological)

Recruiting
  • Breast Cancer
  • Focal Radiation therapy
  • +2 more
  • Los Angeles, California
  • +6 more
Apr 29, 2022

Metastatic Castration-resistant Prostate Cancer Trial in United States (drug, radiation, device)

Completed
  • Metastatic Castration-resistant Prostate Cancer
  • NKTR-214 (Cohort A)
  • +6 more
  • Los Angeles, California
  • +5 more
Nov 10, 2022

Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Head and Neck Squamous Cell Carcinoma Trial in New York (Pembrolizumab, Flt3L,

Recruiting
  • Non-Hodgkin's Lymphoma
  • +2 more
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Oct 18, 2021

Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma Trial in Buffalo (biological, drug, other)

Completed
  • Fallopian Tube Carcinoma
  • +2 more
  • DEC-205/NY-ESO-1 Fusion Protein CDX-1401
  • +4 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 20, 2021

Acute Myeloid Leukemia, Blasts 30 Percent or Less of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia Trial in

Completed
  • Acute Myeloid Leukemia
  • +5 more
  • DEC-205/NY-ESO-1 Fusion Protein CDX-1401
  • +4 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Oct 4, 2021

Low-Grade B-cell Lymphoma Trial in New York (rhuFlt3L/CDX-301, Poly-ICLC)

Recruiting
  • Low-Grade B-cell Lymphoma
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Nov 17, 2020

Melanoma Trial in New York, Philadelphia (Trametinib daily Until PD, CDX-3379 (ERBB3 antibody))

Terminated
Has Results
  • Melanoma
  • Trametinib daily Until PD
  • CDX-3379 (ERBB3 antibody)
  • New York, New York
  • +1 more
May 12, 2020

Eosinophilic Esophagitis Trial (barzolvolimab, Matching Placebo)

Not yet recruiting
  • Eosinophilic Esophagitis
  • barzolvolimab
  • Matching Placebo
  • (no location specified)
Mar 7, 2023

NSCLC, Gastric Cancer, Head Neck Cancer Trial (CDX-585)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +13 more
  • (no location specified)
Mar 29, 2023

Prurigo Nodularis Trial in Germany, United States (CDX-0159, Normal saline)

Recruiting
  • Prurigo Nodularis
  • CDX-0159
  • Normal saline
  • Tempe, Arizona
  • +18 more
Jan 4, 2023

Chronic Inducible Urticaria Trial in United States (barzolvolimab, Matching Placebo)

Recruiting
  • Chronic Inducible Urticaria
  • barzolvolimab
  • Matching Placebo
  • Birmingham, Alabama
  • +31 more
Jan 20, 2023

Cold Urticaria, Cold Contact Urticaria, Symptomatic Dermographism Trial in Berlin (CDX-0159)

Active, not recruiting
  • Cold Urticaria
  • +4 more
  • Berlin, Germany
    Charite University
Dec 20, 2022

Chronic Spontaneous Urticaria Trial in Germany, United States (CDX-0159, Normal Saline)

Completed
  • Chronic Spontaneous Urticaria
  • Birmingham, Alabama
  • +13 more
Jan 24, 2023

Chronic Spontaneous Urticaria Trial in Hungary, United States (barzolvolimab, Matching Placebo)

Recruiting
  • Chronic Spontaneous Urticaria
  • barzolvolimab
  • Matching Placebo
  • Birmingham, Alabama
  • +44 more
Dec 8, 2022

Melanoma, NSCLC, Breast Cancer Trial in United States (CDX-1140, CDX-301, Pembrolizumab)

Completed
  • Melanoma
  • +25 more
  • Scottsdale, Arizona
  • +10 more
Sep 27, 2022

Healthy Subjects Trial in Lincoln (CDX-0159, Normal saline)

Completed
  • Healthy Subjects
  • Lincoln, Nebraska
    Celerion, Inc
Jan 20, 2022

Squamous Cell Carcinoma of the Lung Trial in United States (Phase I: Glembatumumab Vedotin, Phase II: Glembatumumab Vedotin)

Terminated
Has Results
  • Squamous Cell Carcinoma of the Lung
  • Phase I: Glembatumumab Vedotin
  • Phase II: Glembatumumab Vedotin
  • Miami, Florida
  • +9 more
Jun 21, 2019